Kalaris Therapeutics Inc (KLRS)

$2.67 +0.03 (1.14%)
Market Cap 49.37M
Revenue (ttm) 0.00
Net Income (ttm) -58.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,800
Avg Vol 53,800
Day's Range N/A - N/A
Shares Out 18.70M
Stochastic %K 21%
Beta 0.49
Analysts Strong Sell
Price Target $20.50

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Address:
628 Middlefield Road, Palo Alto, United States
Latest News on KLRS
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Jun 2, 2025, 8:00 AM EDT - 15 days ago

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

May 23, 2025, 11:03 AM EDT - 24 days ago

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 8:00 AM EDT - 4 weeks ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Apr 4, 2025, 8:00 AM EDT - 2 months ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir

Mar 18, 2025, 4:21 PM EDT - 3 months ago

Kalaris Announces Closing of Merger with AlloVir

ALVR